Investigational drug · Phase 3
Befotertinib
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
14
Any phase or sponsor naming "Befotertinib"
First trial start
2023
Mar 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Befotertinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- EGFR Sensitive Mutation
- Adjuvant Therapy
- NSCLC
- Adjuvant Drug Therapy
- EGFR
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Befotertinib" as an intervention, largest first.
Fudan UniversityAcademic, hospital or other
NCT06561620 · 592 participants (planned) · Start May 1, 2024 · Primary completion May 1, 2027
Drug: Befotertinib · For: 3-year Disease-free Survival
Sites: Shanghai, China
- Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive MutationsPivotal-lookingRecruiting
Betta Pharmaceuticals Co., Ltd.Industry
NCT06041776 · 570 participants (planned) · Start Mar 28, 2023 · Primary completion Apr 30, 2028
Drug: Befotertinib + Icotinib placebo; Icotinib + Befotertinib placebo · For: Non-Small Cell Lung Cancer; EGFR Sensitive Mutation; Adjuvant Therapy
Sites: Beijing, China; Nanjing, China; Shanghai, China
- Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive MutationNot yet recruiting
Betta Pharmaceuticals Co., Ltd.Industry
NCT06015568 · 172 participants (planned) · Start Sep 1, 2023 · Primary completion Nov 4, 2028
Drug: MCLA-129: 1500mg or 2000mg IV Q2W; Befotertinib: 75 mg or 100 mg Po QD · For: Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
Sites: Bengbu, China; Changsha, China; Shanghai, China
Guangzhou University of Traditional Chinese MedicineAcademic, hospital or other
NCT07709585 · 124 participants (planned) · Start Nov 30, 2026 · Primary completion Jul 31, 2030
Drug: Befotinib; Pemetrexed + Cisplatin /Carboplatin · For: Advanced Non-small Cell Lung Cancer (NSCLC); EGFR Exon 19 Deletion Mutation; EGFR Exon 21 Mutation and 1 more
Sites: Guangzhou, China · 2 sites in all
- A Clinical Study Comparing the Efficacy and Safety of Befotertinib Versus Icotinib in Patients With Previously Untreated EGFR-sensitive Mutation-positive Non-small Cell Lung Cancer With ECOG Score ≥2Pivotal-lookingNot yet recruiting
Zhou ChengzhiAcademic, hospital or other
NCT07900243 · 100 participants (planned) · Start Nov 30, 2026 · Primary completion Dec 31, 2028
Drug: Befotertinib; Icotinib · For: Locally Advanced or Metastatic Non-small Cell Lung Cancer With Previously Untreated EGFR-sensitive Mutations and ECOG Performance Status Score ≥2
- Therapy for Advanced NSCLC With EGFR 19delins MutationNot yet recruiting
Fuzhou General HospitalAcademic, hospital or other
NCT07458919 · 94 participants (planned) · Start Mar 30, 2026 · Primary completion Oct 30, 2030
Drug: Icotinib/Gefitinib · For: Lung Cancer
- ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With RadiotherapyNot yet recruiting
Hebei Medical University Fourth HospitalAcademic, hospital or other
NCT07410611 · 84 participants (planned) · Start Feb 10, 2026 · Primary completion Feb 28, 2030
Drug: Befotertinib · For: Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination
Sites: Shijiazhuang, China
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT06863506 · 78 participants (planned) · Start Oct 1, 2024 · Primary completion Jun 30, 2027
Drug: befotertinib · For: NSCLC (Non-small Cell Lung Cancer)
Sites: Hangzhou, China
Li-kun ChenAcademic, hospital or other
NCT06728865 · 70 participants (planned) · Start Sep 4, 2024 · Primary completion Feb 1, 2028
Drug: The treatment regimen is Befotertinib combined with Bevacizumab. · For: Non-small Cell Lung Cancer (NSCLC); EGFR Mutation-Positive Lung Cancer; Brain Metastases and 2 more
Sites: Guangzhou, China
Peng ZhangAcademic, hospital or other
NCT06755684 · 60 participants (planned) · Start Nov 7, 2024 · Primary completion Dec 31, 2025
Drug: Befotertinib combined Bevacizumab; Befotertinib combined platinum-based double chemotherapy · For: EGFR; Non-Small Cell Lung Cancer; Locally Advanced Non-Small Cell Lung Cancer and 5 more
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.
Mahato S, Mudgal S, Singh H, et al. · J Egypt Natl Canc Inst 2026
- Neoadjuvant befotertinib plus vorolanib in resectable stage II-IIIB EGFR-mutant NSCLC: a study protocol for the prospective, single-arm phase I/II trial.
Wu L, Cai L, Chen D, et al. · Transl Lung Cancer Res 2026
- Attenuation of ABCG2-dependent drug efflux by befotertinib restores chemosensitivity in multidrug-resistant non-small cell lung cancer cells.
Li YC, Chen TY, Chuang HC, et al. · Biomed Pharmacother 2026
- First-line third-generation EGFR-TKIs for advanced EGFR-mutated non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.
Liu X, Zhao Q, Sun W, et al. · J Thorac Dis 2026
- Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making.
Zhao S, Liu X, Wang J, et al. · Cancer Treat Rev 2026
- Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).
Xie Z, Chen X, Gao R, et al. · Chin Med J (Engl) 2026
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.